

BIOTECH INSIDERS

with Lou Kassa

From the PABC



Be sure to like & subscribe!



ENTREPRENEUR SPOTLIGHT

POWERED BY HATCH BIOFUND

JULY 18, 2024
3-5 p.m. EDT

*The winning company will receive
an investment of 250K!*



Est. by the Hepatitis B Foundation



SAVE THE
DATE

HEPATITIS B FOUNDATION

Gala

FRIDAY, APRIL 4, 2025

THE WARRINGTON
1360 Almshouse Road, Warrington, PA

www.hepbgala.org

PROGRAM

Welcome & Intro: Lou Kassa, MPA, CEO , Hepatitis B Foundation, Pennsylvania Biotechnology Center (PABC) & Blumberg Institute

VIP Remarks

Bob Harvie, Bucks Co. Commissioner
Sen. Steve Santarsiero

Emcee: Lorenzo Pellegrini, PhD, Managing Partner, Hatch Biofund

Introduction of Panel:

Eric Heil, MBA, Medical Excellence Capital
Rick Jones, MD, MBA, BioAdvance
Kathie Jordan, PhD, Ben Franklin Technologies
Jim Nelson, MBA, Venable LLP

Company Presentations

Eliksa Therapeutics, Armen Karamanian, MD, PhD
ThirdLaw Molecular, Christian Schafmeister, PhD
HULA Therapeutics, Steve Gelone, PharmD

Networking Hour

*Please complete your voting
within 5 minutes.
The **winner** will be announced
during the networking hour.*



Getting Tested &
Vaccinated is an
important step in
protecting yourself
and your family
against the
Hepatitis B Virus

Visit www.hepb.org
and learn where to
start.



**Discovery - Safety Assessment - Metabolism
Integrated IND programs - Bioanalysis**

Plan your next nonclinical study with us for an
IND-/CTA-enabling package to get you from
research to clinical trials faster



www.labcorp.com/biopharma/nonclinical-studies

TUNNELL ∞
life sciences consulting



Berwyn, PA Cambridge, MA Bethesda, MD

Proud supporter of Entrepreneur Spotlight



**Local Attorneys.
National Resources.**

Pennsylvania knowledge & connections – 1000 attorneys in more than 70 practice areas coast to coast.

That's the Fox Rothschild Advantage.



Fox Rothschild LLP
ATTORNEYS AT LAW
www.foxrothschild.com

Elizabeth Sigety
esigety@foxrothschild.com | 215.918.3554

Loren David Danzis
ldanzis@foxrothschild.com | 215.918.3561

FEATURED COMPANY



Based at the PABC in Doylestown, Eliksa Therapeutics is developing secretome-based therapies to address significant unmet needs in ocular, cardiovascular and osteoarthritic conditions. These therapies have emerged as a promising approach to overcome the traditional limitations associated with cell-based treatments. Eliksa's lead product candidate, ELK-003, is being developed to treat ocular manifestations of Epidermolysis Bullosa and entered clinical trials in 2024.



ARMEN KARAMANIAN, MD, PHD
CO-FOUNDER & CEO

ThermoFisher
SCIENTIFIC



For the love of innovation
Igniting inspiration and driving progress

FEATURED COMPANY



ThirdLaw Molecular, based in Blue Bell, Pa., is developing technologies from Temple University. The company is working to advance its Spiroligomer™ molecules as an innovative, patent-protected, new class of targeted medicines. The company's mission is to create a revolutionary category of molecules that transform how diseases are treated more safely and effectively.



CHRISTIAN SCHAFMEISTER, PHD

PRESIDENT, CSO, FOUNDER, PROFESSOR OF CHEMISTRY



Give your
business a boost

univest.net | 877.723.5571



See what's possible.

Forward Together

Venable is proud to support the 10th Annual Entrepreneur Spotlight as it showcases and supports efforts to advance biotechnology discoveries and develop the next generation of researchers.

VENABLE LLP

CA | CO | DC | DE | FL | IL | MD | NY | VA

Prajakta A. Sonalkar, Ph.D.
151 W. 42nd Street, New York, NY | Attorney advertising

**SAVE
THE DATE**

2024 Regional
Biotechnology
Conference

NOV. 14, 2024 EST

Baruch S.
BLUMBERG
INSTITUTE

PENNSYLVANIA
BIOTECHNOLOGY CENTER

THIS EVENT IS POWERED BY



Hatch Biofund is a life sciences venture capital firm headquartered in the Philadelphia region and affiliated with the Pennsylvania Biotechnology Center in Doylestown, Pa. Hatch was formed to provide early-stage capital to promising local life science companies, along with access to deep industry expertise and physical platforms to help them realize their missions.



LORENZO PELLEGRINI, PHD
MANAGING PARTNER

Lorenzo has overall responsibilities for Hatch's investing and operating activities. He is a scientist, investor and entrepreneur with 30 years of experience in the life sciences and is committed to translating scientific discoveries into products that make a difference in patients' lives.

Lorenzo was the founder or co-founder of six biotech companies, as either sole founder or venture capital equity co-founder and manager. Prior to joining Hatch, he was the Founder of Palladio Biosciences, a drug development company developing innovative drugs for the treatment of rare kidney diseases. Serving as Palladio's first CEO, he raised \$20 million in venture capital financing and advanced the company's lead drug from IND to Phase 2 studies.

FEATURED COMPANY



HULA Therapeutics is dedicated to bringing safer and more efficacious therapies for children and adults with solid tumors.

Leveraging a novel target discovery engine developed at Children's Hospital of Philadelphia, the company aims to be in the clinic in late 2024 with a CAR-T cell therapy for neuroblastoma. HULA Therapeutics also is working on programs for sarcoma, medulloblastoma and gliomas.



STEVE GELONE, PHARM D
PRESIDENT & CEO

PANELISTS



KATHIE JORDAN, PHD

*MANAGING DIRECTOR,
BEN FRANKLIN TECHNOLOGY PARTNERS*



JAMES E. NELSON, MBA

PARTNER, VENABLE LLP

PANELISTS



ERIC HEIL, MBA

*MANAGING PARTNER,
MEDICAL EXCELLENCE CAPITAL*



FREDERICK JONES, MD, MBA

PARTNER, BIOADVANCE